In one RCT, Bcl-2 was targeted by the Bcl-2 inhibitor AT-101 to boost radiotherapy efficiency in head and neck squamous cell carcinoma (HNSCC). This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.